Erdheim-Chester Disease (ECD): Understanding Your Pathology Report

Section Editor: David Li MD
July 1, 2026

Erdheim-Chester disease (ECD) is a rare type of blood and immune system cancer called a histiocytic neoplasm. It develops when abnormal immune cells called histiocytes build up in tissues throughout the body, surrounded by scar tissue (fibrosis). Because the cells fill with fat, they look pale and bubbly under the microscope and are described as “foamy.” Erdheim-Chester disease is one of a group of conditions called non-Langerhans cell histiocytoses, which sets it apart from Langerhans cell histiocytosis, a related disorder with different cells and markers. Although it was once thought to be an inflammatory reaction, it is now understood to be a neoplasm (a tumor) driven by genetic changes in the cells. The disease usually affects several organs at once and most often develops in adults.

This article will help you understand the findings in your pathology report for Erdheim-Chester disease, what each term means, and why it matters for your care.

Where does Erdheim-Chester disease occur?

Erdheim-Chester disease (ECD) can involve multiple organs simultaneously. Some patterns are so typical that they help suggest the diagnosis:

Bones — The most commonly affected site. The long bones of the legs are typically involved on both sides in a symmetric pattern, with thickening and hardening of the bone (osteosclerosis).
Kidneys and retroperitoneum — The tissue at the back of the abdomen and around the kidneys can become infiltrated, producing an appearance on imaging sometimes called “hairy kidney.”
Heart and large blood vessels — The tissue around the aorta can be involved, producing a “coated aorta” appearance, and masses can form in the heart.
Brain, nervous system, and pituitary gland — Involvement here can cause neurological symptoms, and damage to the pituitary gland can cause diabetes insipidus, a condition that leads to excessive thirst and frequent urination.
Eyes, skin, and lungs — The tissue behind the eye can be affected, yellowish deposits can appear on the skin (often around the eyelids), and the lungs can be involved.

What are the symptoms of Erdheim-Chester disease?

The symptoms of Erdheim-Chester disease (ECD) depend on which organs are involved, and the disease often develops slowly over years before it is recognized. The most common symptom is bone pain, usually in the legs. Other symptoms depend on the affected organs and may include excessive thirst and frequent urination (from diabetes insipidus), neurological problems such as difficulty with balance or coordination, bulging or pressure around the eyes, kidney problems, and symptoms related to the heart or blood vessels. Many patients also have general symptoms such as fatigue, fever, weight loss, and night sweats.

How common is Erdheim-Chester disease?

Erdheim-Chester disease (ECD) is very rare, with only a small number of cases identified each year worldwide. It is most often diagnosed in adults between the ages of 40 and 70 and affects men slightly more often than women. It is rare in children. In some patients, Erdheim-Chester disease occurs alongside Langerhans cell histiocytosis or another bone marrow blood disorder, reflecting their shared origin in the same cell lineage.

What causes Erdheim-Chester disease?

Erdheim-Chester disease (ECD) is caused by acquired genetic mutations (changes in the DNA) that develop during a person’s life and are not inherited. These changes affect a signaling pathway inside cells called the MAPK pathway, which normally controls how cells grow and survive. When the pathway is continuously activated, the abnormal histiocytes survive for too long and accumulate in tissues. Because the cells all share the same genetic change, Erdheim-Chester disease is considered a clonal neoplasm rather than a simple inflammatory reaction. The specific genes involved are described in the section on genetic changes below.

How is the diagnosis made?

The diagnosis of Erdheim-Chester disease (ECD) requires integrating findings from biopsy, imaging, and genetic testing, as no single test is sufficient on its own. A biopsy is taken from affected tissue, such as bone, the area around the kidney, or the skin, and examined under the microscope by a pathologist. The typical finding is an infiltrate of foamy histiocytes (histiocytes filled with fat) set in a background of fibrosis, often mixed with other immune cells and sometimes containing large multinucleated cells called Touton giant cells.

Because foamy histiocytes can be seen in other conditions, immunohistochemistry is used to confirm the identity of the cells. In Erdheim-Chester disease, histiocytes typically express CD68, CD163, and factor XIIIa, and are negative for CD1a and CD207 (langerin). The S100 protein is usually negative or only weakly positive. This pattern is important because it separates Erdheim-Chester disease from Langerhans cell histiocytosis, whose cells are positive for CD1a, CD207, and S100. Testing for the BRAF V600E mutation, described below, is also part of the workup. Imaging is essential to complete the diagnosis, because patterns such as symmetric thickening of the leg bones, the “hairy kidney” appearance around the kidneys, and the “coated aorta” appearance around the main blood vessel strongly support the diagnosis.

Genetic changes and molecular testing in Erdheim-Chester disease

Genetic testing is a critical part of evaluating Erdheim-Chester disease (ECD) because it both supports the diagnosis and guides treatment. About half of all cases carry the BRAF V600E mutation, which switches on the MAPK pathway. Cases without this change often have mutations in other genes of the same pathway, such as MAP2K1, ARAF, NRAS, or KRAS, or in the related PI3K-AKT pathway. Rarely, the disease is driven by gene fusions involving genes such as ALK or NTRK.

Testing may be performed in several ways. A special immunohistochemistry stain can detect the BRAF V600E protein directly in the tissue. Next-generation sequencing and PCR-based testing look for BRAF and other mutations, and in some cases, testing can be done on a blood sample to detect tumor DNA when a tissue sample is limited. The result is usually reported by naming the gene and the specific change, such as BRAF V600E or a MAP2K1 mutation, and described as present (positive) or not detected (negative). Identifying the mutation matters because it determines whether targeted therapy is likely to work.

What is the prognosis for Erdheim-Chester disease?

The outlook for Erdheim-Chester disease (ECD) depends mainly on which organs are involved and how widespread the disease is. Involvement of the central nervous system or the heart and blood vessels is associated with a higher risk. In the past, the outlook was often poor, but the discovery that the disease is driven by the MAPK pathway has transformed treatment. With modern targeted therapies, many patients now have a much better outlook, including long-term disease control. Your prognosis depends on your own combination of these factors, which your care team can explain in the context of your specific report.

What happens after a diagnosis of Erdheim-Chester disease?

After Erdheim-Chester disease (ECD) is diagnosed, treatment depends on which organs are involved and which genetic change is present. The pathology and molecular findings help guide several decisions:

Targeted therapy for BRAF V600E — When the BRAF V600E mutation is present, BRAF inhibitors (such as vemurafenib or dabrafenib) can be highly effective and have become a main treatment.
Targeted therapy for other mutations — When the disease is driven by a different MAPK pathway change, MEK inhibitors (such as cobimetinib or trametinib) may be used.
Other systemic treatments — Before targeted drugs were available, interferon-alpha was the main treatment, and it is still an option in some situations. Other medicines, such as anakinra or sirolimus, are used in selected cases.
Treatment of diabetes insipidus — When the pituitary gland is affected, hormone replacement with desmopressin manages excessive thirst and urination, often long-term.
Observation — Patients with very limited disease and no symptoms may be monitored closely rather than treated right away.

Because Erdheim-Chester disease can affect many organs, care is usually shared among several specialists, and long-term follow-up with imaging and clinical assessment is important for monitoring treatment response. Clinical trials of newer therapies may also be an option to discuss. Decisions about treatment are made by the care team together with the patient, based on the specific findings in the report.

Questions to ask your doctor

Which organs are affected by my Erdheim-Chester disease?
What did my biopsy and immunohistochemistry results show?
Was the BRAF V600E mutation found, or another MAPK pathway change?
Could I benefit from targeted therapy such as a BRAF or MEK inhibitor?
Is my heart, blood vessels, or nervous system involved?
Is my pituitary gland affected, and am I at risk for diabetes insipidus?
What imaging tests will I need, and how often?
What is my prognosis based on my specific findings?
Which specialists will be involved in my care?
Are there clinical trials that I should consider?